Biologics and heart failure in rheumatoid arthritis: Are we any wiser?

Current Opinion in Rheumatology

Volumn 20, Issue 3, 2008, Pages 327-333

  Danila, Maria I ^a   Patkar, Nivedita M ^a   Curtis, Jeffrey R ^a   Saag, Kenneth G ^a   Teng, Gim Gee ^b  

^a The University of Alabama at Birmingham   (United States)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Anti TNF agents; Biologic disease modifying antirheumatic drugs; Heart failure; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

HEART FAILURE; HUMAN; INCIDENCE; MONOTHERAPY; MORTALITY; NONHUMAN; OSTEOARTHRITIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; TREATMENT CONTRAINDICATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; HEART FAILURE; HUMANS; IMMUNOLOGIC FACTORS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41649110444     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282fb03d8     Document Type: Review

References (61)

1. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004; 109:1594-1602.
2. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebocontrolled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107:3133-3140.
3. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003; 30:36-40.
4. Mutru O, Laakso M, Isomaki H, Koota K. Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology 1989; 76:71-77.
5. Nicola PJ, Crowson CS, Maradit-Kremers H, et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 2006; 54:60-67.
6. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of antitumor necrosis factor therapy. Am J Med 2004; 116:305-311.
7. Gabriel SE, Crowson CS, Luthra HS, et al. Modeling the lifetime costs of rheumatoid arthritis. J Rheumatol 1999; 26:1269-1274.
8. Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005; 52:412-420.
9. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48:54-58.
10. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37:481-494.
11. Chehata JC, Hassell AB, Clarke SA, et al. Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology (Oxford) 2001; 40:447-452.
12. Crowson CS, Nicola PJ, Kremers HM, et al. How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum 2005; 52:3039-3044.
13. del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44:2737-2745.
14. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24:445-451.
15. Davis JM 3rd, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007; 56:820-830.
16. Goodson NJ, Wiles NJ, Lunt M, et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002; 46:2010-2019.
17. Gonzalez A, Maradit Kremers H, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007; 56:3583-3587.
18. Gonzalez A, Maradit Kremers H, Crowson CS, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in nonrheumatoid arthritis patients? Ann Rheum Dis 2008; 67:64-69. Traditional cardiac risk factors impart a lower risk for cardiovascular events among patients with RA compared with those without RA.
19. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. The increased risk of ventricular diastolic dysfunction and congestive heart failure in patients with rheumatoid arthritis is independent of the duration of the disease. Semin Arthritis Rheum 2005; 35:132-133.
20. Wislowska M, Jaszczyk B, Kochmanski M, et al. Diastolic heart function in RA patients. Rheumatol Int 2007 [Epub ahead of print].
21. Meune C, Wahbi K, Assous N, et al. Myocardial dysfunction in rheumatoid arthritis: a controlled tissue-Doppler echocardiography study. J Rheumatol 2007; 34:2005-2009.
22. Di Franco M, Paradiso M, Mammarella A, et al. Diastolic function abnormalities in rheumatoid arthritis. Evaluation by echo Doppler transmitral flow and pulmonary venous flow: relation with duration of disease. Ann Rheum Dis 2000; 59:227-229.
23. Levendoglu F, Temizhan A, Ugurlu H, et al. Ventricular function abnormalities in active rheumatoid arthritis: a Doppler echocardiographic study. Rheumatol Int 2004; 24:141-146.
24. Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000; 35:537-544.
25. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236-241.
26. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996; 27:1201-1206.
27. Ono K, Matsumori A, Shioi T, et al. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 1998; 98:149-156.
28. Kapadia S, Lee J, Torre-Amione G, et al. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995; 96:1042-1052.
29. Kapadia SR, Oral H, Lee J, et al. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 1997; 81:187-195.
30. Irwin MW, Mak S, Mann DL, et al. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation 1999; 99:1492-1498.
31. Moro C, Marie-Gabrielle J, Rakotovao A, et al. Delayed expression of cytokines after reperfused myocardial infarction: possible trigger for cardiac dysfunction and ventricular remodelling. Am J Physiol Heart Circ Physiol 2007 [Epub ahead of print]. A study showing that the expression of TNF-a one week after myocardial infaction is associated with maximal infarct expansion and altered ventricular compliance.
32. Sun M, Chen M, Dawood F, et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 2007; 115:1398-1407. A study showing myocardial TNF-a contributes to adverse left ventricular remodeling during pressure overload, which leads to cardiac dysfunction.
33. Murray DR, Freeman GL. Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res 1996; 78:154-160.
34. Elahi M, Asopa S, Matata B. NO-cGMP and TNF-alpha counter regulatory system in blood: understanding the mechanisms leading to myocardial dysfunction and failure. Biochim Biophys Acta 2007; 1772:5-14.
35. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J 1991; 66:356-358.
36. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102:3060-3067.
37. Sanchez-Lazaro IJ, Almenar L, Reganon E, et al. Inflammatory markers in stable heart failure and their relationship with functional class. Int J Cardiol 2007 [Epub ahead of print]. This study shows that TNF-a is directly correlated to heart failure functional class, but not to left ventricular ejection fraction.
38. Rodriguez-Reyna TS, Arrieta O, Castillo-Martinez L, et al. Tumour necrosis factor alpha and troponin T as predictors of poor prognosis in patients with stable heart failure. Clin Invest Med 2005; 28:23-29.
39. Kosar F, Aksoy Y, Ozguntekin G, et al. Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail 2006; 8:270-274.
40. Zimmermann O, Kochs M, Zwaka TP, et al. Prognostic role of myocardial tumor necrosis factor-alpha and terminal complement complex expression in patients with dilated cardiomyopathy. Eur J Heart Fail 2007; 9:51-54. This study shows that myocardial TNF-α is not a good marker for assessing clinical outcome in patients with cardiomyopathy.
41. Hofmann U, Heuer S, Meder K, et al. The proinflammatory cytokines TNFalpha and IL-1beta impair economy of contraction in human myocardium. Cytokine 2007; 39:157-162. A study showing that both TNF-α and IL-1β have cardiodepressant effects on human atrial tissue.
42. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765.
43. Kaur K, Sharma AK, Singal PK. Significance of changes in TNF-alpha and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. Am J Physiol Heart Circ Physiol 2006; 291:H106-H113.
44. Kaur K, Sharma AK, Dhingra S, Singal PK. Interplay of TNF-alpha and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes. J Mol Cell Cardiol 2006; 41:1023-1030.
45. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 2006; 54:2807-2816.
46. Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006; 54:1075-1086.
47. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50:3432-3443.
48. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138:807-811.
49. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65:889-894.
50. Feltelius N, Fored CM, Blomqvist P, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005; 64:246-252.
51. Cole J, Busti A, Kazi S. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int 2007; 27:369-373.
52. Bernatsky S, Hudson M, Suissa S. Antirheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44:677-680.
53. Curtis JR, Kramer JM, Martin C, et al. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. Rheumatology (Oxford) 2007; 46:1688-1693. Meticulous methods for ascertaining outcome of heart failure. Slight increase in numbers without statistical significance of incident heart failure in the younger patients receiving TNF-α antagonists.
54. Carmona L, Descalzo MA, Perez-Pampin E, et al. All-cause and causespecific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007; 66:880-885. A study of population based cohorts showed a decreased all-cause mortality rate ratio in RA patients on anti-TNFa agents compared with those not exposed, with major contribution from a lowered mortality due to cardiovascular diseases.
55. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:614-624.
56. Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004; 63:1062-1068.
57. Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65:1006-1012.
58. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006; 144:865-876.
59. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 2007; 66:228-234.
60. Ghielmini M, Schmitz SF, Burki K, et al. The effect of rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000; 11 (Suppl 1):123-126.
61. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19:2165-2170.